Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib-Cyclophosphamide-Dexamethasone versus Lenalidomide-Cyclophosphamide-Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma
ChiCTR2000029863Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ixazomib, lenalidomide, cyclophosphamide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Overall response rate. Planned start Mar 2020; status: not yet recruiting.
02
Drugs
ixazomiblenalidomidecyclophosphamidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2000029863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029863.